| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Gene (CYP17) Polymorphism Is Associated with Serum Estrogen and Progesterone Concentrations1
Departments of Preventive Medicine [H. S. F., L. S. S., M. C. P., B. E. H.], Urology [G. A. C.], and Obstetrics and Gynecology [F. Z. S.], University of Southern California School of Medicine and University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California 90033-0800
An increased level of serum estrogen is one marker of breast cancer risk. We have recently reported that increased risk of advanced breast cancer is associated with a common allele of the cytochrome P450c17
gene (CYP17), designated A2. We now show that CYP17 genotype is associated with serum hormone levels among 83 young, nulliparous women. Serum estradiol (E2) levels measured around day 11 of the menstrual cycle were 11 and 57% higher (P = 0.04), respectively, among women hetero- and homozygous for the CYP17 A2 allele compared to A1/A1 women. Similarly, around cycle day 22, E2 levels were 7 and 28% higher (P = 0.06), and progesterone levels were 24 and 30% higher (P = 0.04), respectively. These data provide direct evidence of genetic control of serum hormone levels.
1 This work was supported by funds from the California Breast Cancer Research Program of the University of California (Grants 2FB-0212 and 1KB-0060) and by NCI Grant CA14089-21.
2 To whom requests for reprints should be addressed, at Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, MS44, Los Angeles, CA 90033-0800. Phone: (213) 764-0419; Fax: (213) 764-0127.
Received 10/15/97. Accepted 1/ 2/98.
This article has been cited by other articles:
|
|
 |
|
  B. Diergaarde, J. D. Potter, E. R. Jupe, S. Manjeshwar, C. D. Shimasaki, T. W. Pugh, D. C. DeFreese, B. A. Gramling, I. Evans, and E. White Polymorphisms in Genes Involved in Sex Hormone Metabolism, Estrogen Plus Progestin Hormone Therapy Use, and Risk of Postmenopausal Breast Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2008; 17(7): 1751 - 1759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Chen, M. D. Gammon, S. L. Teitelbaum, J. A. Britton, M. B. Terry, S. Shantakumar, S. M. Eng, Q. Wang, I. Gurvich, A. I. Neugut, et al. Estrogen-biosynthesis gene CYP17 and its interactions with reproductive, hormonal and lifestyle factors in breast cancer risk: results from the Long Island Breast Cancer Study Project Carcinogenesis, April 1, 2008; 29(4): 766 - 771. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. T. Campbell, L. Edwards, J. R. McLaughlin, J. Green, H. B. Younghusband, and M. O. Woods Cytochrome P450 17A1 and Catechol O-Methyltransferase Polymorphisms and Age at Lynch Syndrome Colon Cancer Onset in Newfoundland Clin. Cancer Res., July 1, 2007; 13(13): 3783 - 3788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. V. Dimitrov, P. Colucci, and S. Nagpal Some Aspects of the Endocrine Profile and Management of Hormone-Dependent Male Breast Cancer Oncologist, July 1, 2007; 12(7): 798 - 807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, D. J. Tomso, B. N. Chorley, H.-Y. Cho, V. G. Cheung, S. R. Kleeberger, and D. A. Bell Identification of polymorphic antioxidant response elements in the human genome Hum. Mol. Genet., May 15, 2007; 16(10): 1188 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Henningson, U. Johansson, A. Borg, H. Olsson, and H. Jernstrom CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women Mol. Hum. Reprod., April 1, 2007; 13(4): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Olson, E. V. Bandera, and I. Orlow Variants in Estrogen Biosynthesis Genes, Sex Steroid Hormone Levels, and Endometrial Cancer: A HuGE Review Am. J. Epidemiol., February 1, 2007; 165(3): 235 - 245. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jasienska, M. Kapiszewska, P. T. Ellison, M. Kalemba-Drozdz, I. Nenko, I. Thune, and A. Ziomkiewicz CYP17 Genotypes Differ in Salivary 17-{beta} Estradiol Levels: A Study Based on Hormonal Profiles from Entire Menstrual Cycles. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2131 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. W. Setiawan, C. A. Haiman, F. Z. Stanczyk, L. Le Marchand, and B. E. Henderson Racial/Ethnic differences in postmenopausal endogenous hormones: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev., October 1, 2006; 15(10): 1849 - 1855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.H. Juo, T.N. Wang, J.N. Lee, M.T. Wu, C.Y. Long, and E.M. Tsai CYP17, CYP1A1 and COMT polymorphisms and the risk of adenomyosis and endometriosis in Taiwanese women Hum. Reprod., June 1, 2006; 21(6): 1498 - 1502. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Piller, E. Verla-Tebit, S. Wang-Gohrke, J. Linseisen, and J. Chang-Claude CYP17 Genotype Modifies the Association between Lignan Supply and Premenopausal Breast Cancer Risk in Humans J. Nutr., June 1, 2006; 136(6): 1596 - 1603. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. F. Skibola, P. M. Bracci, R. A. Paynter, M. S. Forrest, L. Agana, T. Woodage, K. Guegler, M. T. Smith, and E. A. Holly Polymorphisms and Haplotypes in the Cytochrome P450 17A1, Prolactin, and Catechol-O-Methyltransferase Genes and Non-Hodgkin Lymphoma Risk Cancer Epidemiol. Biomarkers Prev., October 1, 2005; 14(10): 2391 - 2401. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Small, M. Marcus, S. L. Sherman, A. K. Sullivan, A. K. Manatunga, and H. S. Feigelson CYP17 genotype predicts serum hormone levels among pre-menopausal women Hum. Reprod., August 1, 2005; 20(8): 2162 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lurie, G. Maskarinec, R. Kaaks, F. Z. Stanczyk, and L. Le Marchand Association of Genetic Polymorphisms with Serum Estrogens Measured Multiple Times During a 2-Year Period in Premenopausal Women Cancer Epidemiol. Biomarkers Prev., June 1, 2005; 14(6): 1521 - 1527. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C. Onland-Moret, C. H. van Gils, M. Roest, D. E. Grobbee, and P. H.M. Peeters Cyp17, Urinary Sex Steroid Levels and Breast Cancer Risk in Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 815 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Kok, N. C. Onland-Moret, K. M. van Asselt, C. H. van Gils, Y. T. van der Schouw, D. E. Grobbee, and P. H.M. Peeters No association of estrogen receptor {alpha} and cytochrome P450c17{alpha} polymorphisms with age at menopause in a Dutch cohort Hum. Reprod., February 1, 2005; 20(2): 536 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Dunn, D. L. Wickerham, and L. G. Ford Prevention of Hormone-Related Cancers: Breast Cancer J. Clin. Oncol., January 10, 2005; 23(2): 357 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Weiss, K. B. Moysich, and H. Swede Epidemiology of Male Breast Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 20 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. C. Travis, M. Churchman, S. A. Edwards, G. Smith, P. K. Verkasalo, C. R. Wolf, H. Wolf, and T. J. Key No Association of Polymorphisms in CYP17, CYP19, and HSD17-B1 with Plasma Estradiol Concentrations in 1,090 British Women Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2282 - 2284. [Full Text] [PDF]
|
|
|
|
|
|
L. Sharp, A. H. Cardy, S. C. Cotton, and J. Little CYP17 Gene Polymorphisms: Prevalence and Associations with Hormone Levels and Related Factors. A HuGE Review Am. J. Epidemiol., October 15, 2004; 160(8): 729 - 740. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yamada, F. Sata, E. H. Kato, Y. Saijo, S. Kataoka, M. Morikawa, S. Shimada, T. Yamada, R. Kishi, and H. Minakami A polymorphism in the CYP17 gene and intrauterine fetal growth restriction Mol. Hum. Reprod., January 1, 2004; 10(1): 49 - 53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Sata, H. Yamada, A. Yamada, E. H. Kato, S. Kataoka, Y. Saijo, T. Kondo, J. Tamaki, H. Minakami, and R. Kishi A polymorphism in the CYP17 gene relates to the risk of recurrent pregnancy loss Mol. Hum. Reprod., November 1, 2003; 9(11): 725 - 728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. E. McCann, K. B. Moysich, J. L. Freudenheim, C. B. Ambrosone, and P. G. Shields The Risk of Breast Cancer Associated with Dietary Lignans Differs by CYP17 Genotype in Women J. Nutr., October 1, 2002; 132(10): 3036 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Pike, L. N. Kolonel, B. E. Henderson, L. R. Wilkens, J. H. Hankin, H. S. Feigelson, P. C. Wan, D. O. Stram, and A. M. Y. Nomura Breast Cancer in a Multiethnic Cohort in Hawaii and Los Angeles: Risk Factor-adjusted Incidence in Japanese Equals and in Hawaiians Exceeds that in Whites Cancer Epidemiol. Biomarkers Prev., September 1, 2002; 11(9): 795 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Kado, J. Kitawaki, H. Obayashi, H. Ishihara, H. Koshiba, I. Kusuki, K. Tsukamoto, G. Hasegawa, N. Nakamura, T. Yoshikawa, et al. Association of the CYP17 gene and CYP19 gene polymorphisms with risk of endometriosis in Japanese women Hum. Reprod., April 1, 2002; 17(4): 897 - 902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M M de Jong, I M Nolte, G J te Meerman, W T A van der Graaf, J C Oosterwijk, J H Kleibeuker, M Schaapveld, and E G E de Vries Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility J. Med. Genet., April 1, 2002; 39(4): 225 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ye and J. M. Parry The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis Mutagenesis, March 1, 2002; 17(2): 119 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-W. Yu, Y.-C. Yang, S.-Y. Yang, S.-W. Cheng, Y.-F. Liaw, S.-M. Lin, and C.-J. Chen Hormonal Markers and Hepatitis B Virus-Related Hepatocellular Carcinoma Risk: a Nested Case-Control Study Among Men J Natl Cancer Inst, November 7, 2001; 93(21): 1644 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Taplin and S.-M. Ho The Endocrinology of Prostate Cancer J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477. [Full Text] [PDF]
|
|
|
|
|
|
C. A. Haiman, M. J. Stampfer, E. Giovannucci, J. Ma, N. E. Decalo, P. W. Kantoff, and D. J. Hunter The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Prostate Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2001; 10(7): 743 - 748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Armstrong Genetic Susceptibility to Breast Cancer: From the Roll of the Dice to the Hand Women Were Dealt JAMA, June 13, 2001; 285(22): 2907 - 2909. [Full Text] [PDF]
|
|
|
|
|
|
M. T. Goodman, K. McDuffie, C. Guo, K. Terada, and T. A. Donlon CYP17 Genotype and Ovarian Cancer: A Null Case-Control Study Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 563 - 564. [Full Text]
|
|
|
|
 |
|
 C. A. Haiman, S. E. Hankinson, G. A. Colditz, D. J. Hunter, and I. De Vivo A Polymorphism in CYP17 and Endometrial Cancer Risk Cancer Res., May 1, 2001; 61(10): 3955 - 3960. [Abstract] [Full Text]
|
|
|
|
|
|
N. E. Allen, M. S. Forrest, and T. J. Key The Association between Polymorphisms in the CYP17 and 5{{alpha}}-Reductase (SRD5A2) Genes and Serum Androgen Concentrations in Men Cancer Epidemiol. Biomarkers Prev., March 1, 2001; 10(3): 185 - 189. [Abstract] [Full Text]
|
|
|
|
|
|
R. McKean-Cowdin, H. S. Feigelson, M. C. Pike, G. A. Coetzee, L. N. Kolonel, and B. E. Henderson Risk of Endometrial Cancer and Estrogen Replacement Therapy History by CYP17 Genotype Cancer Res., February 1, 2001; 61(3): 848 - 849. [Abstract] [Full Text]
|
|
|
|
|
|
H. S. Feigelson, R. McKean-Cowdin, G. A. Coetzee, D. O. Stram, L. N. Kolonel, and B. E. Henderson Building a Multigenic Model of Breast Cancer Susceptibility: CYP17 and HSD17B1 Are Two Important Candidates Cancer Res., January 1, 2001; 61(2): 785 - 789. [Abstract] [Full Text]
|
|
|
|
|
|
K. Mitrunen, N. Jourenkova, V. Kataja, M. Eskelinen, V.-M. Kosma, S. Benhamou, H. Vainio, M. Uusitupa, and A. Hirvonen Steroid Metabolism Gene CYP17 Polymorphism and the Development of Breast Cancer Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1343 - 1348. [Abstract] [Full Text]
|
|
|
|
|
|
A. B. Spurdle, J. L. Hopper, G. S. Dite, X. Chen, J. Cui, M. R. E. McCredie, G. G. Giles, M. C. Southey, D. J. Venter, D. F. Easton, et al. CYP17 Promoter Polymorphism and Breast Cancer in Australian Women Under Age Forty Years J Natl Cancer Inst, October 18, 2000; 92(20): 1674 - 1681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Habuchi, Z. Liqing, T. Suzuki, R. Sasaki, N. Tsuchiya, H. Tachiki, N. Shimoda, S. Satoh, K. Sato, Y. Kakehi, et al. Increased Risk of Prostate Cancer and Benign Prostatic Hyperplasia Associated with a CYP17 Gene Polymorphism with a Gene Dosage Effect Cancer Res., October 1, 2000; 60(20): 5710 - 5713. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Thompson and C. Ambrosone Chapter 7: Molecular Epidemiology of Genetic Polymorphisms in Estrogen Metabolizing Enzymes in Human Breast Cancer J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Henderson and H. S. Feigelson Hormonal carcinogenesis Carcinogenesis, March 1, 2000; 21(3): 427 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Coughlin and M. Piper Genetic Polymorphisms and Risk of Breast Cancer Cancer Epidemiol. Biomarkers Prev., November 1, 1999; 8(11): 1023 - 1032. [Full Text]
|
|
|
|
|
|
C.-S. Huang, H.-D. Chern, K.-J. Chang, C.-W. Cheng, S.-M. Hsu, and C.-Y. Shen Breast Cancer Risk Associated with Genotype Polymorphism of the Estrogen-metabolizing Genes CYP17, CYP1A1, and COMT: A Multigenic Study on Cancer Susceptibility Cancer Res., October 1, 1999; 59(19): 4870 - 4875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Lunn, D. A. Bell, J. L. Mohler, and J. A. Taylor Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2) Carcinogenesis, September 1, 1999; 20(9): 1727 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. S. Feigelson, R. McKean-Cowdin, M. C. Pike, G. A. Coetzee, L. N. Kolonel, A. M. Y. Nomura, L. L. Marchand, and B. E. Henderson Cytochrome P450c17{{alpha}} Gene (CYP17) Polymorphism Predicts Use of Hormone Replacement Therapy Cancer Res., August 1, 1999; 59(16): 3908 - 3910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. N. Kristensen, E. K. Haraldsen, K. B. Anderson, P. E. Lonning, B. Erikstein, R. Karesen, O. S. Gabrielsen, and A.-L. Borresen-Dale CYP17 and Breast Cancer Risk: The Polymorphism in the 5' Flanking Area of the Gene Does Not Influence Binding to Sp-1 Cancer Res., June 1, 1999; 59(12): 2825 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Haiman, S. E. Hankinson, D. Spiegelman, G. A. Colditz, W. C. Willett, F. E. Speizer, K. T. Kelsey, and D. J. Hunter The Relationship between a Polymorphism in CYP17 with Plasma Hormone Levels and Breast Cancer Cancer Res., March 1, 1999; 59(5): 1015 - 1020. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
